

Synvista Therapeutics, Inc.
 Form 3/A
 January 03, 2008

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Atticus Capital LP		(Month/Day/Year)	Synvista Therapeutics, Inc. [SYI]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
		07/25/2007		08/20/2007
767 FIFTH AVENUE, 12TH FLOOR,Â			(Check all applicable)	
(Street)			<input type="checkbox"/> Director	<input checked="" type="checkbox"/> 10% Owner
			<input type="checkbox"/> Officer	<input type="checkbox"/> Other
NEW YORK,Â NYÂ 10153			(give title below)	(specify below)
(City)	(State)	(Zip)	6. Individual or Joint/Group Filing(Check Applicable Line)	
			<input type="checkbox"/> Form filed by One Reporting Person	
			<input checked="" type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

(Instr. 5)

Series B Preferred Stock, \$0.01 par value per share <u>(1)</u>	Â <u>(2)</u>	Â <u>(3)</u>	Common Stock	1,600,000	\$ 2.5	I	See Note <u>(4)</u> <u>(5)</u>
Series B Preferred Stock Purchase Warrants (right to buy) <u>(1)</u>	Â <u>(2)</u>	07/25/2012	Common Stock <u>(1)</u>	400,000	\$ 2.5	I	See Note <u>(4)</u> <u>(5)</u>

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Atticus Capital LP 767 FIFTH AVENUE, 12TH FLOOR NEW YORK, NY 10153	Â	Â X	Â	Â
ATTICUS MANAGEMENT LTD P.O. BOX 100, SYDNEY VANE HOUSE ADMIRAL PARK ST. PETER PORT, GUERNSEY GY1 3EL	Â	Â X	Â	Â
BARAKETT TIMOTHY R C/O ATTICUS CAPITAL LP 767 FIFTH AVENUE, 12TH FLOOR NEW YORK, NY 10153	Â	Â X	Â	Â

Signatures

/s/ Timothy R. Barakett, individually; as Chairman and Chief Executive Officer of Atticus Capital LP, by Dennis Bertron, attorney-in-fact 01/03/2008

__Signature of Reporting Person

Date

/s/ Dennis Bertron, as attorney-in-fact for Atticus Management Limited 01/03/2008

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Series B Preferred Stock Purchase Warrants represent the right to buy 400,000 shares of Series B Preferred Stock. Each share of Series B Preferred Stock is convertible into one share of Common Stock.
 - (2) Immediately
 - (3) None
 - (4) This amendment to the Form 3 previously filed on August 20, 2007 by (i) Atticus Holdings LP ("Atticus Holdings"), a Delaware limited partnership formerly known as Atticus Capital LP, (ii) Atticus Management LLC, and (iii) Mr. Timothy R. Barakett ("Mr. Barakett" and, together with Atticus Holdings and Atticus Management LLC, the "Former Reporting Persons"). Due to an internal reorganization completed by the Former Reporting Persons, this amendment is being filed by (x) Atticus Management Limited, a Guernsey company, (y) Atticus Capital LP, a newly formed Delaware limited partnership and (z) Mr. Barakett (collectively, the "Reporting Persons"). For further information on this restructuring please see the Schedule 13D/A filed by the Reporting Persons on January 3, 2008.
 - (5) As a result, each of the Reporting Persons may be deemed to be a beneficial owner of the securities owned by the Funds and Accounts for purposes of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934. The Reporting Persons disclaim beneficial ownership within the

Edgar Filing: Synvista Therapeutics, Inc. - Form 3/A

meaning of Rule 16a-1(a)(2) under the Securities Exchange Act of 1934 in the securities owned by the Funds and the Accounts except to the extent, if any, of their pecuniary interest therein.

Â

Remarks:

ExhibitÂ List:

ExhibitÂ 24.1Â Â Â Â Â PowerÂ ofÂ Attorney,Â datedÂ JuneÂ 7,Â 2007

ExhibitÂ 24.2Â Â Â Â Â PowerÂ ofÂ Attorney,Â datedÂ DecemberÂ 28,Â 2007

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.